806,780 Shares in Quince Therapeutics, Inc. $QNCX Acquired by Ieq Capital LLC

Key Points

• Ieq Capital LLC has acquired 806,780 shares of Quince Therapeutics, valued at approximately $1,073,000, representing about 1.83% of the company.
• Analysts have provided mixed ratings for Quince Therapeutics, with a current average rating of "Buy" and an average target price of $8.14.
• The company recently reported a loss of ($0.34) earnings per share for the quarter, missing the consensus estimate, while predicting an average loss of -1.21 for the current year.

Ieq Capital LLC bought a new position in Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 806,780 shares of the company's stock, valued at approximately $1,073,000. Ieq Capital LLC owned about 1.83% of Quince Therapeutics at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Shay Capital LLC grew its position in shares of Quince Therapeutics by 60.8% during the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company's stock worth $518,000 after buying an additional 104,616 shares during the period. Intellectus Partners LLC acquired a new position in Quince Therapeutics during the first quarter valued at approximately $71,000. Northern Trust Corp boosted its holdings in shares of Quince Therapeutics by 48.5% in the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company's stock valued at $94,000 after buying an additional 16,501 shares during the period. Virtu Financial LLC boosted its holdings in shares of Quince Therapeutics by 48.4% in the first quarter. Virtu Financial LLC now owns 43,332 shares of the company's stock valued at $58,000 after buying an additional 14,128 shares during the period. Finally, Two Sigma Investments LP acquired a new position in shares of Quince Therapeutics in the fourth quarter valued at approximately $57,000. 30.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

QNCX has been the topic of a number of research reports. JMP Securities cut their price objective on shares of Quince Therapeutics from $9.00 to $8.00 and set a "market outperform" rating on the stock in a research report on Tuesday, August 12th. D. Boral Capital reissued a "buy" rating and issued a $4.00 price objective on shares of Quince Therapeutics in a research report on Friday, August 15th. Citigroup began coverage on shares of Quince Therapeutics in a research report on Tuesday, August 5th. They set an "outperform" rating on the stock. Zacks Research raised shares of Quince Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 26th. Finally, Wall Street Zen downgraded shares of Quince Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Quince Therapeutics currently has an average rating of "Buy" and an average target price of $8.14.

Quince Therapeutics Stock Up 0.3%

Shares of NASDAQ QNCX traded up $0.01 during trading on Friday, hitting $1.61. The stock had a trading volume of 86,570 shares, compared to its average volume of 161,724. Quince Therapeutics, Inc. has a 12 month low of $0.68 and a 12 month high of $2.45. The company has a debt-to-equity ratio of 1.45, a current ratio of 5.00 and a quick ratio of 5.00. The company has a market capitalization of $86.47 million, a PE ratio of -1.48 and a beta of 0.99. The firm has a fifty day moving average of $1.68 and a two-hundred day moving average of $1.38.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). As a group, equities research analysts forecast that Quince Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.